Research Progress on miR-143 and miR-145 in Esophageal Cancer

Volume 7, Issue 6, December 2022     |     PP. 361-375      |     PDF (279 K)    |     Pub. Date: December 11, 2022
DOI: 10.54647/cm32969    92 Downloads     3047 Views  

Author(s)

Minggang Du, Clinical Medical College, Jiamusi University, China

Abstract
Esophageal cancer is one of the malignancies that with high occurrence in China. Its high morbidity and mortality have caused huge disease burden for the society. Therefore, it is getting necessary to elucidate the molecular mechanisms regarding the onset and progression of esophageal cancer. Increasing studies suggest that miR-143 and miR-145 are differentially expressed and deeply involved in the progression, chemotherapy resistance, radiotherapy resistance and other processes in esophageal cancer. The two miRNAs also associate with the prognosis of patients with esophageal cancer. Discussing the roles of miR-143 and miR-145 in esophageal cancer may further contribute to ascertain their relevant molecular mechanisms and clarify the value of the two miRNAs as potential biomarkers and molecular targets, in an attempt to provide new insights for the clinical treatment of esophageal cancer.

Keywords
miR-143, miR-145, esophageal cancer, ERK signaling pathway, p38 signaling pathway, JAK/STAT signaling pathway, PI3K/AKT signaling pathway, Wnt signaling pathway

Cite this paper
Minggang Du, Research Progress on miR-143 and miR-145 in Esophageal Cancer , SCIREA Journal of Clinical Medicine. Volume 7, Issue 6, December 2022 | PP. 361-375. 10.54647/cm32969

References

[ 1 ] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249.
[ 2 ] Domper Arnal MJ, Ferrández Arenas Á, Lanas Arbeloa Á. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015 Jul 14;21(26):7933-43. doi: 10.3748/wjg.v21.i26.7933.
[ 3 ] Kent OA, McCall MN, Cornish TC, et al. Lessons from miR-143/145: the importance of cell-type localization of miRNAs. Nucleic Acids Res. 2014 Jul;42(12):7528-38. doi: 10.1093/nar/gku461.
[ 4 ] Akao Y, Nakagawa Y, Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep. 2006 Oct;16(4):845-50.
[ 5 ] Zhang Y, Wang Z, Chen M, et al. MicroRNA-143 targets MACC1 to inhibit cell invasion and migration in colorectal cancer. Mol Cancer. 2012 Apr 25;11:23. doi: 10.1186/1476-4598-11-23.
[ 6 ] Takagi T, Iio A, Nakagawa Y, et al. Decreased expression of microRNA-143 and -145 in human gastric cancers. Oncology. 2009;77(1):12-21. doi: 10.1159/000218166.
[ 7 ] Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018 Apr;141(4):1202-1207. doi: 10.1016/j.jaci.2017.08.034.
[ 8 ] Saliminejad K, Khorram Khorshid HR, Soleymani Fard S, et al. An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 2019 May;234(5):5451-5465. doi: 10.1002/jcp.27486.
[ 9 ] Singh RP, Massachi I, Manickavel S, et al. The role of miRNA in inflammation and autoimmunity. Autoimmun Rev. 2013 Oct;12(12):1160-5. doi: 10.1016/j.autrev.2013.07.003.
[ 10 ] Castaño C, Kalko S, Novials A, et al. Obesity-associated exosomal miRNAs modulate glucose and lipid metabolism in mice. Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):12158-12163. doi: 10.1073/pnas.1808855115.
[ 11 ] Cardona E, Guyomar C, Desvignes T, et al. Circulating miRNA repertoire as a biomarker of metabolic and reproductive states in rainbow trout. BMC Biol. 2021 Nov 16;19(1):235. doi: 10.1186/s12915-021-01163-5.
[ 12 ] Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol. 2009;4:199-227. doi: 10.1146/annurev.pathol.4.110807.092222.
[ 13 ] Skrzypek K, Kot M, Konieczny P, et al. SNAIL Promotes Metastatic Behavior of Rhabdomyosarcoma by Increasing EZRIN and AKT Expression and Regulating MicroRNA Networks. Cancers (Basel). 2020 Jul 11;12(7):1870. doi: 10.3390/cancers12071870.
[ 14 ] Poli V, Seclì L, Avalle L. The Microrna-143/145 Cluster in Tumors: A Matter of Where and When. Cancers (Basel). 2020 Mar 17;12(3):708. doi: 10.3390/cancers12030708.
[ 15 ] Shimonosono M, Idichi T, Seki N, et al. Molecular pathogenesis of esophageal squamous cell carcinoma: Identification of the antitumor effects of miR1453p on gene regulation. Int J Oncol. 2019 Feb;54(2):673-688. doi: 10.3892/ijo.2018.4657.
[ 16 ] Derouet MF, Dakpo E, Wu L, et al. miR-145 expression enhances integrin expression in SK-GT-4 cell line by down-regulating c-Myc expression. Oncotarget. 2018 Mar 8;9(20):15198-15207. doi: 10.18632/oncotarget.24613.
[ 17 ] Dai Y, Zang Y, Li J, et al. miR-181a and miR-203 inhibit migration and invasion of laryngeal carcinoma cells by interacting with ATF2. Int J Clin Exp Pathol. 2019 Jan 1;12(1):133-141.
[ 18 ] Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014 Jan 16;505(7483):344-52. doi: 10.1038/nature12986.
[ 19 ] Michael MZ, O' Connor SM, van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003 Oct;1(12):882-91.
[ 20 ] Wu BL, Xu LY, Du ZP, et al. MiRNA profile in esophageal squamous cell carcinoma: downregulation of miR-143 and miR-145. World J Gastroenterol. 2011 Jan 7;17(1):79-88. doi: 10.3748/wjg.v17.i1.79.
[ 21 ] Liu R, Liao J, Yang M, et al. The cluster of miR-143 and miR-145 affects the risk for esophageal squamous cell carcinoma through co-regulating fascin homolog 1. PLoS One. 2012;7(3):e33987. doi: 10.1371/journal.pone.0033987.
[ 22 ] Mao Y, Liu J, Zhang D, et al. miR-143 inhibits tumor progression by targeting FAM83F in esophageal squamous cell carcinoma. Tumour Biol. 2016 Jul;37(7):9009-22. doi: 10.1007/s13277-015-4760-9.
[ 23 ] Chen Q, Hou J, Wu Z, et al. miR-145 Regulates the sensitivity of esophageal squamous cell carcinoma cells to 5-FU via targeting REV3L. Pathol Res Pract. 2019 Jul;215(7):152427. doi: 10.1016/j.prp.2019.04.019.
[ 24 ] Jin W, Luo W, Fang W, et al. miR-145 expression level in tissue predicts prognosis of patients with esophageal squamous cell carcinoma. Pathol Res Pract. 2019 Jun;215(6):152401. doi: 10.1016/j.prp.2019.03.029.
[ 25 ] Wang K, Chen D, Meng Y, et al. Clinical evaluation of 4 types of microRNA in serum as biomarkers of esophageal squamous cell carcinoma. Oncol Lett. 2018 Jul;16(1):1196-1204. doi: 10.3892/ol.2018.8720.
[ 26 ] Feber A, Xi L, Pennathur A, et al. MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma. Ann Thorac Surg. 2011 May;91(5):1523-30. doi: 10.1016/j.athoracsur.2011.01.056.
[ 27 ] Mayne GC, Hussey DJ, Watson DI. MicroRNAs and esophageal cancer--implications for pathogenesis and therapy. Curr Pharm Des. 2013;19(7):1211-26. doi: 10.2174/138161213804805702.
[ 28 ] Zhang L, Wang X, Li Y, et al. c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis. Clin Transl Med. 2021 Sep;11(9):e464. doi: 10.1002/ctm2.464.
[ 29 ] Derouet MF, Liu G, Darling GE. MiR-145 expression accelerates esophageal adenocarcinoma progression by enhancing cell invasion and anoikis resistance. PLoS One. 2014 Dec 31;9(12):e115589. doi: 10.1371/journal.pone.0115589.
[ 30 ] Ni Y, Meng L, Wang L, et al. MicroRNA-143 functions as a tumor suppressor in human esophageal squamous cell carcinoma. Gene. 2013 Apr 1;517(2):197-204. doi: 10.1016/j.gene.2012.12.031.
[ 31 ] Xue YJ, Du YY, Huang WH, et al. Effects of miR-143-3p on proliferation, migration and invasion of esophageal cancer cells through MAPK7 pathway. Chinese Journal of Immunology. 2019 Oct; 35(18):2177-2180,2186. doi: 10.3969/j.issn.1000-484X.2019.18.001. [In Chinese]
[ 32 ] Zheng TL, Li DP, He ZF, et al. miR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K/AKT signaling pathway. Cancer Cell Int. 2019 Sep 30;19:250. doi: 10.1186/s12935-019-0943-6.
[ 33 ] Roy S, Kar M, Roy S, et al. Inhibition of CD44 sensitizes cisplatin-resistance and affects Wnt/β-catenin signaling in HNSCC cells. Int J Biol Macromol. 2020 Apr 15;149:501-512. doi: 10.1016/j.ijbiomac.2020.01.131.
[ 34 ] Wei CY, Zhu MX, Yang YW, et al. Downregulation of RNF128 activates Wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma. J Hematol Oncol. 2019 Mar 4;12(1):21. doi: 10.1186/s13045-019-0711-z.
[ 35 ] Schmitt M, Metzger M, Gradl D, et al. CD44 functions in Wnt signaling by regulating LRP6 localization and activation. Cell Death Differ. 2015 Apr;22(4):677-89. doi: 10.1038/cdd.2014.156.
[ 36 ] Yan Y, Zhang C, Li B, et al. Inhibitory effects of microRNA-143 on invasion and metastasis of esophageal cancer by down-regulating Wnt/β-catenin and mechanism. Chinese Journal of Experimental Surgery. 2017 Jun; 34(6):997-1000. doi:10.3760/cma.j.issn.1001-9030.2017.06.030. [In Chinese]
[ 37 ] Chen J, Duan Z, Liu Y, et al. Ginsenoside Rh4 Suppresses Metastasis of Esophageal Cancer and Expression of c-Myc via Targeting the Wnt/β-Catenin Signaling Pathway. Nutrients. 2022 Jul 25;14(15):3042. doi: 10.3390/nu14153042.
[ 38 ] Hu Y, Yu K, Wang G, et al. Lanatoside C inhibits cell proliferation and induces apoptosis through attenuating Wnt/β-catenin/c-Myc signaling pathway in human gastric cancer cell. Biochem Pharmacol. 2018 Apr;150:280-292. doi: 10.1016/j.bcp.2018.02.023.
[ 39 ] Jiang Y, Han Q, Zhao H, et al. Promotion of epithelial-mesenchymal transformation by hepatocellular carcinoma-educated macrophages through Wnt2b/β-catenin/c-Myc signaling and reprogramming glycolysis. J Exp Clin Cancer Res. 2021 Jan 6;40(1):13. doi: 10.1186/s13046-020-01808-3.
[ 40 ] Li HJ, Yang TT, Zhu MX, et al. miR-145 Loaded by Nanoplatelets Targeted Myc Inhibits Proliferation and Migration of Esophageal Cancer Cells. 2020 Sep;2(1):43-49. doi:10.15926/j.cnki.issn2096-7381.2020.01.009. [In Chinese]
[ 41 ] Mei LL, Wang WJ, Qiu YT, et al. miR-145-5p Suppresses Tumor Cell Migration, Invasion and Epithelial to Mesenchymal Transition by Regulating the Sp1/NF-κB Signaling Pathway in Esophageal Squamous Cell Carcinoma. Int J Mol Sci. 2017 Aug 23;18(9):1833. doi: 10.3390/ijms18091833.
[ 42 ] Li Y, Tang C, Huang SH, et al. MicroRNA-145 suppresses esophageal squamous cell carcinoma by targeting phospholipase C epsilon 1. 2017 Oct;34(9):1472-1475. doi:10.3760/cma.j.issn.1001-9030.2017.09.011. [In Chinese]
[ 43 ] Chen Y, Wang D, Peng H, et al. Epigenetically upregulated oncoprotein PLCE1 drives esophageal carcinoma angiogenesis and proliferation via activating the PI-PLCε-NF-κB signaling pathway and VEGF-C/ Bcl-2 expression. Mol Cancer. 2019 Jan 4;18(1):1. doi: 10.1186/s12943-018-0930-x.
[ 44 ] Liu H, Zheng M, Zhao Y, et al. miR-143 inhibits migration and invasion through regulating LASP1 in human esophageal cancer. Int J Clin Exp Pathol. 2019 Feb 1;12(2):466-476.
[ 45 ] Hu M, Zhang Q, Tian XH, et al. lncRNA CCAT1 is a biomarker for the proliferation and drug resistance of esophageal cancer via the miR-143/PLK1/BUBR1 axis. Mol Carcinog. 2019 Dec;58(12):2207-2217. doi: 10.1002/mc.23109.
[ 46 ] Zhang Q, Gan H, Song W, et al. MicroRNA-145 promotes esophageal cancer cells proliferation and metastasis by targeting SMAD5. Scand J Gastroenterol. 2018 Jun-Jul;53(7):769-776. doi: 10.1080/00365521.2018.1476913.
[ 47 ] Shang M, Wang X, Zhang Y, et al. LincRNA-ROR promotes metastasis and invasion of esophageal squamous cell carcinoma by regulating miR-145/FSCN1. Onco Targets Ther. 2018 Jan 31;11:639-649. doi: 10.2147/OTT.S157638.
[ 48 ] Zhang P, He H, Bai Y, et al. Dexmedetomidine suppresses the progression of esophageal cancer via miR-143-3p/epidermal growth factor receptor pathway substrate 8 axis. Anticancer Drugs. 2020 Aug;31(7):693-701. doi: 10.1097/CAD.0000000000000934.
[ 49 ] Fan S, Chen P, Li S. miR-145-5p Inhibits the Proliferation, Migration, and Invasion of Esophageal Carcinoma Cells by Targeting ABRACL. Biomed Res Int. 2021 Feb 26;2021:6692544. doi: 10.1155/2021/6692544.
[ 50 ] Tang C, He JY, Yu C, et al. MicroRNA-145 performs as a tumor suppressor in human esophageal squamous cell carcinoma by targeting phospholipase C epsilon 1. J Cell Biochem. 2019 Jun;120(6):10678-10687. doi: 10.1002/jcb.28358.
[ 51 ] Feng M, Aibibai M, Shi JY, et al. Expression of miR-143, miR-145 and Sur vivin mRNA in esophageal cancers among Kazaks. Carcinogenesis, Teratogenesis & Mutagenesis. 2020 Apr;32(1):29-32. doi:10.3969/j.issn.1004-616x.2020.01.005.
[ 52 ] Fattahi Dolatabadi N, Dehghani A, Shahand E, et al. The interaction between MALAT1 target, miR-143-3p, and RALGAPA2 is affected by functional SNP rs3827693 in breast cancer. Hum Cell. 2020 Oct;33(4):1229-1239. doi: 10.1007/s13577-020-00422-x.
[ 53 ] Yang HJ, Ju F, Guo XX, et al. RNA-binding protein RBM3 prevents NO-induced apoptosis in human neuroblastoma cells by modulating p38 signaling and miR-143. Sci Rep. 2017 Jan 30;7:41738. doi: 10.1038/srep41738.
[ 54 ] Li Q, Yu X, Yang L. MiR-145 inhibits cervical cancer progression and metastasis by targeting WNT2B by Wnt/β-catenin pathway. Int J Clin Exp Pathol. 2019 Oct 1;12(10):3740-3751.
[ 55 ] Miao Y, Zhang LF, Zhang M, et al. Therapeutic Delivery of miR-143 Targeting Tumor Metabolism in Poorly Differentiated Thyroid Cancer Xenografts and Efficacy Evaluation Using 18F-FDG MicroPET-CT. Hum Gene Ther. 2019 Jul;30(7):882-892. doi: 10.1089/hum.2018.160.